A WSJ op-ed piece by Richard Miller, an oncologist and the CEO of the Bay Area-based Pharmacyclics, argues that the FDA needs to get cancer drugs to market quicker. Maybe he should direct his eye toward Scottish scientists at the universities of Glasgow and Strathclyde, who are developing a large molecular sensing device they plan to use to test for signature patterns of drug side effects.